Abstract Background: The GLOBAL LEADERS (GLOBAL LEADERS: A Clinical Study
Comparing Two Forms of Anti-platelet Therapy After Stent Implantation) study randomly …

Background Dual antiplatelet therapy (DAPT) is necessary to prevent thrombosis yet
increases bleeding after percutaneous coronary intervention (PCI) with drug-eluting stents …

Aims To evaluate the impact of an experimental strategy [23-month ticagrelor monotherapy
following 1-month dual antiplatelet therapy (DAPT)] vs. a reference regimen (12-month …

Objectives The aim of this study was to compare ticagrelor monotherapy with dual-
antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with drug-eluting …

Background: The optimal antiplatelet strategy in the second year after percutaneous
coronary intervention (PCI) remains unclear. Aims: We aimed to compare ticagrelor …

Importance Among patients undergoing percutaneous coronary intervention (PCI), it
remains unclear whether the treatment efficacy of P2Y 12 inhibitor monotherapy after a short …

Aims PEGASUS-TIMI 54 demonstrated that long-term dual antiplatelet therapy (DAPT) with
aspirin and ticagrelor reduced the risk of major adverse cardiovascular events (MACE), with …

Background Whether a regimen of ticagrelor monotherapy attenuates bleeding
complications without increasing ischemic risk in patients undergoing complex …

Importance Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was
evaluated as a bleeding reduction strategy. However, the strategy of ticagrelor monotherapy …

Background The optimal duration of dual antiplatelet therapy after coronary drug‐eluting
stent placement in adults with stable coronary artery disease (SCAD) versus acute coronary …